Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

Matthias Schwenkglenks; Toby J Toward; Stephanie Plent; Thomas D Szucs; Daniel J Blackman; Andreas Baumbach

doi:10.1136/heartjnl-2011-301323

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via BCS

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Browse by collection

Authors

About

Podcasts
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via BCS

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Citation Tools

Acute coronary syndromes

Original article

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:: Schwenkglenks M, Toward TJ, Plent S, et al

Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction

Heart 2012;98:544-551.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Download to a citation manager

Read the full text or download the PDF:

Log in using your username and password